A major breakthrough in the fight against COVID-19 has been announced by the World Health Organization (WHO). The organization has approved the use of a new drug, called Sotrovimab, for the treatment of COVID-19 patients.
Sotrovimab, developed by GlaxoSmithKline and Vir Biotechnology, is a monoclonal antibody therapy that has shown promising results in clinical trials. It works by targeting the spike protein of the virus, preventing it from entering and infecting healthy cells.
According to the WHO, Sotrovimab has been found to reduce the risk of hospitalization and death by 85% in high-risk patients. This is a significant development in the fight against the pandemic, as it provides a much-needed treatment option for those who are most vulnerable to severe illness.
Dr. Mariângela Simão, WHO Assistant Director-General for Access to Medicines and Health Products, stated that the approval of Sotrovimab is a “major step forward” in the global effort to control the pandemic. She also emphasized the importance of equitable access to the drug, especially for low- and middle-income countries.
The approval of Sotrovimab by the WHO comes at a crucial time, as the world continues to battle the spread of new variants of the virus. The drug has shown effectiveness against the Delta variant, which is currently the dominant strain in many countries.
However, the WHO also stressed the importance of continuing to follow public health measures, such as wearing masks and practicing social distancing, even with the availability of this new treatment. Vaccination remains the most effective way to prevent severe illness and death from COVID-19.
Sotrovimab is the fifth drug to receive emergency use authorization from the WHO for the treatment of COVID-19. This approval will allow countries to expedite their own regulatory approval processes and make the drug available to their populations.
The fight against COVID-19 is far from over, but the approval of Sotrovimab offers a glimmer of hope in these challenging times. With continued efforts to vaccinate and the availability of effective treatments, we can move closer to ending this global health crisis.
